Immunotherapy has fundamentally reshaped the landscape of lung cancer treatment, offering a beacon of hope and significantly improving patient prognoses.…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotechnology firm formerly known as Somite AI, has announced a significant strategic acquisition, securing global rights…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
For millions globally afflicted by actinic keratoses (AKs), the rough, scaly patches of sun-damaged skin that serve as precursors to…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
A transformative partnership has been forged between Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, and Eli Lilly, a…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says.
Amazon Web Services (AWS) has announced the launch of Amazon Bio Discovery, a groundbreaking application designed to revolutionize the speed…
Read More
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
In a strategic maneuver that underscores the intensifying competition in the life sciences technology sector, Salesforce has announced that over…
Read More
How Immuto Scientific pairs AI and mass spec for a step change in protein structure throughput
Immuto Scientific, a trailblazing company co-founded in 2018 by CEO Faraz A. Choudhury, Ph.D., and CTO Daniel Benjamin, Ph.D., both…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More
The $1.8 Billion Telehealth Conundrum: Medvi’s Rise Amidst Regulatory Gaps, AI Deception, and the Compounded Drug Market
A recent profile by The New York Times celebrated Medvi, a burgeoning telehealth enterprise, as a testament to the transformative…
Read MoreYOU MAY HAVE MISSED
